Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer

Vascular disrupting agents (VDAs) represent a relatively distinct class of agents that target established blood vessels in tumors. In this study, we examined the preclinical activity of the second-generation VDA OXi4503 against human head and neck squamous cell carcinoma (HNSCC). Studies were perfor...

Full description

Bibliographic Details
Main Authors: Katelyn D. Bothwell, Margaret Folaron, Mukund Seshadri
Format: Article
Language:English
Published: MDPI AG 2016-01-01
Series:Cancers
Subjects:
Online Access:http://www.mdpi.com/2072-6694/8/1/11